Benutzerbeiträge
- 07:25, 19. Jan. 2018 (Unterschied | Versionen) . . (+3.666 Bytes) . . N And/or severe IRRs and lymphocyte count B5000/ll in cycle (Die Seite wurde neu angelegt: „BEN)c BEN 90 mg/m d1 ? 2 cycles 1? ? G 1000 mg d1, d8, and d15 cycle 1, then d1 cycles two? and maintenance 1000 mg every two mo (if no PD) for 2 yrs or until…“) (aktuell)
- 07:06, 19. Jan. 2018 (Unterschied | Versionen) . . (+4.019 Bytes) . . N Maintenance (if CR/PR/SD) 9 two yrs or till PD75 FL; 12 othersTable (Die Seite wurde neu angelegt: „[75] Phase I; r/r NHL mc, ol, dose escalationAEs [http://www.tongji.org/members/sheet24chord/activity/610729/ Ofessional groups are usually not moving to claim…“)
- 09:03, 18. Jan. 2018 (Unterschied | Versionen) . . (+3.467 Bytes) . . N Ent had been ongoing in between information cutoff and interim evaluation, and (Die Seite wurde neu angelegt: „[83] r/r FLPhase Ib; mc, ol, rGAUDI (first-line)Dyer et al. [84] FL (first-line)Phase Ib; mc, ol, rTable two continuedNo.Ent had been ongoing involving informa…“)
- 05:39, 18. Jan. 2018 (Unterschied | Versionen) . . (+3.414 Bytes) . . N Es (Table 1). Most notably, all CLL patients treated inside the GAUGUIN (Die Seite wurde neu angelegt: „The ORR in the end of induction was greater with obinutuzumab than with rituximab, as shown by investigator assessments in the end with the induction period (4…“) (aktuell)
- 08:17, 17. Jan. 2018 (Unterschied | Versionen) . . (-300 Bytes) . . K Ent had been ongoing in between data cutoff and interim evaluation, and (aktuell)
- 07:52, 17. Jan. 2018 (Unterschied | Versionen) . . (+3.394 Bytes) . . N Ent had been ongoing in between data cutoff and interim evaluation, and (Die Seite wurde neu angelegt: „PFS was drastically longer with combination therapy (median not reached) than with bendamustine aloneCOMBINATION THERAPYPhase I and II Following the promising…“)